These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 30102201)
41. The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events. Kawaguchi T; Azuma K; Sano M; Kim S; Kawahara Y; Sano Y; Shimodaira T; Ishibashi K; Miyaji T; Basch E; Yamaguchi T J Patient Rep Outcomes; 2017; 2(1):2. PubMed ID: 29757309 [TBL] [Abstract][Full Text] [Related]
42. Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period. Lee MK; Basch E; Mitchell SA; Minasian LM; Langlais BT; Thanarajasingam G; Ginos BF; Rogak LJ; Mendoza TR; Bennett AV; Schrag D; Mazza GL; Dueck AC Qual Life Res; 2023 Jul; 32(7):2047-2058. PubMed ID: 36897529 [TBL] [Abstract][Full Text] [Related]
43. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278 [TBL] [Abstract][Full Text] [Related]
44. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940 [TBL] [Abstract][Full Text] [Related]
45. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. Basch E; Dueck AC; Rogak LJ; Mitchell SA; Minasian LM; Denicoff AM; Wind JK; Shaw MC; Heon N; Shi Q; Ginos B; Nelson GD; Meyers JP; Chang GJ; Mamon HJ; Weiser MR; Kolevska T; Reeve BB; Bruner DW; Schrag D J Clin Oncol; 2018 Sep; 36(31):JCO2018788620. PubMed ID: 30204536 [TBL] [Abstract][Full Text] [Related]
46. Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Sio TT; Atherton PJ; Birckhead BJ; Schwartz DJ; Sloan JA; Seisler DK; Martenson JA; Loprinzi CL; Griffin PC; Morton RF; Anders JC; Stoffel TJ; Haselow RE; Mowat RB; Wittich MA; Bearden JD; Miller RC Support Care Cancer; 2016 Sep; 24(9):3847-55. PubMed ID: 27075674 [TBL] [Abstract][Full Text] [Related]
47. Clinician-observed and patient-reported toxicities and their association with poor tolerance to therapy in older patients with head and neck or lung cancer treated with curative radiotherapy. Moon DH; Chera BS; Deal AM; Wang Y; Muss HB; VanderWalde NA J Geriatr Oncol; 2019 Jan; 10(1):42-47. PubMed ID: 29903673 [TBL] [Abstract][Full Text] [Related]
48. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Miyaji T; Iioka Y; Kuroda Y; Yamamoto D; Iwase S; Goto Y; Tsuboi M; Odagiri H; Tsubota Y; Kawaguchi T; Sakata N; Basch E; Yamaguchi T J Patient Rep Outcomes; 2017; 1(1):8. PubMed ID: 29757296 [TBL] [Abstract][Full Text] [Related]
49. Monitoring Adverse Effects of Radiation Therapy in Patients With Head and Neck Cancer: The FACT-HN-RAD Patient-Reported Outcome Measure. Gharzai LA; Mierzwa ML; Peipert JD; Kirtane K; Casper K; Yadav P; Rothrock N; Cella D; Shaunfield S JAMA Otolaryngol Head Neck Surg; 2023 Oct; 149(10):884-890. PubMed ID: 37589994 [TBL] [Abstract][Full Text] [Related]
50. Comparing the patients' subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires. Holländer-Mieritz C; Johansen J; Johansen C; Vogelius IR; Kristensen CA; Pappot H Acta Oncol; 2019 May; 58(5):603-609. PubMed ID: 30698098 [No Abstract] [Full Text] [Related]
51. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial. Wintner LM; Giesinger JM; Sztankay M; Bottomley A; Holzner B; Trials; 2020 Oct; 21(1):849. PubMed ID: 33050917 [TBL] [Abstract][Full Text] [Related]
52. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors. Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984 [TBL] [Abstract][Full Text] [Related]
53. Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. Yeung AR; Pugh SL; Klopp AH; Gil KM; Wenzel L; Westin SN; Gaffney DK; Small W; Thompson S; Doncals DE; Cantuaria GHC; Yaremko BP; Chang A; Kundapur V; Mohan DS; Haas ML; Kim YB; Ferguson CL; Deshmukh S; Bruner DW; Kachnic LA J Clin Oncol; 2020 May; 38(15):1685-1692. PubMed ID: 32073955 [TBL] [Abstract][Full Text] [Related]
54. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Basch E; Becker C; Rogak LJ; Schrag D; Reeve BB; Spears P; Smith ML; Gounder MM; Mahoney MR; Schwartz GK; Bennett AV; Mendoza TR; Cleeland CS; Sloan JA; Bruner DW; Schwab G; Atkinson TM; Thanarajasingam G; Bertagnolli MM; Dueck AC Clin Trials; 2021 Feb; 18(1):104-114. PubMed ID: 33258687 [TBL] [Abstract][Full Text] [Related]
55. Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development. Xia H; Booth BP; Wang Y; Fan C; Bhatnagar V; Kluetz P; Fourie Zirkelbach J J Patient Rep Outcomes; 2023 Nov; 7(1):116. PubMed ID: 37975967 [TBL] [Abstract][Full Text] [Related]
56. Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study. Underwood J; McCloskey S; Raldow A; Kishan A; Zalkin C; Navarro D; Holt LS; Webb A; Lynch KA; Atkinson TM JMIR Form Res; 2022 Apr; 6(4):e27775. PubMed ID: 35412466 [TBL] [Abstract][Full Text] [Related]
57. Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure. Feldman E; Pos FJ; Smeenk RJ; van der Poel H; van Leeuwen P; de Feijter JM; Hulshof M; Budiharto T; Hermens R; de Ligt KM; Walraven I ESMO Open; 2023 Feb; 8(1):100775. PubMed ID: 36652781 [TBL] [Abstract][Full Text] [Related]
58. Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy. Taarnhøj GA; Lindberg H; Johansen C; Pappot H J Patient Rep Outcomes; 2019 Aug; 3(1):56. PubMed ID: 31440865 [TBL] [Abstract][Full Text] [Related]
59. Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Schroeder KM; Rizzieri T; Lion RR; Mtenga N; Gisiri M; McFatrich M; Reeve BB J Patient Rep Outcomes; 2023 Jun; 7(1):56. PubMed ID: 37306774 [TBL] [Abstract][Full Text] [Related]
60. Translation Into Simplified Chinese and Cultural Validation of the Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Using Cognitive Interviewing. Shen N; Ruan H; Sun J; Li Y; He M; Yuan C; Chang L Cancer Nurs; 2023 Jan-Feb 01; 46(1):E31-E40. PubMed ID: 35583994 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]